Effect of Stellate Ganglion Block on Postoperative Nausea and Vomiting
Effect of Right⁃Stellate Ganglion Block on Postoperative Nausea and Vomiting in Patients Undergoing Thyroid Surgery
1 other identifier
interventional
200
1 country
1
Brief Summary
Postoperative nausea and vomiting is one of the most common postoperative complications second only to postoperative pain. Studies have reported that without any antiemetic prevention treatment, the overall incidence of PONV in surgical operations is up to 20-30%, and the incidence of PONV in high-risk patients such as thyroid surgery is even up to 70-80%. PONV not only increased discomfort and prolonged hospital stay; Severe cases can lead to wound dehysis, acid-base imbalance, water and electrolyte metabolism disorders, seriously affect the prognosis of patients. Although various prevention and treatment measures have been adopted in clinical practice, it still cannot be completely eliminated. Therefore, postoperative nausea and vomiting of thyroid is still a concern in clinical anesthesia work, so it is urgent to explore more simple and effective measures to prevent thyroid PONV. SGB is the injection of local anesthetics into loose connective tissue containing stellate ganglion. It has a clear effect on postoperative analgesia of thyroid surgery, and can play a certain role in preventing thyroid PONV by reducing the application of perioperative opioids. Few studies have reported that the incidence of PONV can be significantly reduced after the application of SGB in patients with thyroid surgery, which provides a certain basis for the prevention of thyroid PONV. Therefore, this study aims to explore the effect of right stellate ganglion block on preventing postoperative nausea and vomiting of thyroid, and to explore the possible mechanism of action.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Apr 2023
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 17, 2023
CompletedFirst Submitted
Initial submission to the registry
April 14, 2024
CompletedFirst Posted
Study publicly available on registry
April 17, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
August 30, 2024
CompletedApril 26, 2024
April 1, 2023
1.1 years
April 14, 2024
April 24, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Incidence of Postoperative nausea and vomiting
Postoperative nausea and vomiting is evaluated by follow-up
From end of surgery to 24 hours after surgery
Secondary Outcomes (8)
Incidence of Postoperative nausea and vomiting during preemptive analgesia
From 0-10 min after preemptive analgesia
Intensity of nausea and vomiting during preemptive analgesia
From 0-10 min after preemptive analgesia
Intensity of nausea and vomiting during hospitalization
From end of surgery to 24 hours after surgery
Hemodynamic parameters after preemptive analgesia
From 0-10 min after preemptive analgesia
Postoperative pain intensity
From end of surgery to 24 hours after surgery
- +3 more secondary outcomes
Study Arms (2)
Right stellate ganglion block
EXPERIMENTALRight -stellate ganglion block was given 30minutes before anesthesia induction.
Blank control group
NO INTERVENTIONNo treatment was given 30 minutes before anesthesia induction
Interventions
The experimental group was given right stellate ganglion block 30 minutes before anesthesia induction
Eligibility Criteria
You may qualify if:
- Receiving thyroid surgery under general anesthesia
- Age ≥18 years and ≤ 70 years
- American Society of Anesthesiologists(ASA) physical status classification I-III.
- Voluntary participation and ability to understand and sign the informed consent form.
You may not qualify if:
- Patients with obesity(BMI\>30 kg/m2)
- contraindicated to stellate ganglion block
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, 400000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
ling Dan, BD
The Second Affiliated Hospital of Chongqing Medical University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- TRIPLE
- Who Masked
- PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 14, 2024
First Posted
April 17, 2024
Study Start
April 17, 2023
Primary Completion
May 30, 2024
Study Completion
August 30, 2024
Last Updated
April 26, 2024
Record last verified: 2023-04
Data Sharing
- IPD Sharing
- Will share
all IPD that underlie results in a publication